FIA
PRNB

FNY Investment Advisers’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

FNY Investment Advisers’s Portfolio PRNB Stock Details PRNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-145
Closed -$4K – 1168
2018
Q3 		$4K Buy
+145
New +$4.09K ﹤0.01% 651

Other funds holding PRNB

NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
MMPI
Morgenthaler Management Partners IX Portola Valley, California $22.6M AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

FNY Investment Advisers's PRNB Position: Q4 2018 in Review

FNY Investment Advisers sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q4 2018, closing a stake of 145 shares — an estimated $4K sold.

FNY Investment Advisers first reported a position in PRNB in Q3 2018 and held it in 1 quarter. The position peaked at $4K in Q3 2018. 53 funds tracked by Wall St. Rank hold PRNB as of Q4 2018.

  • FNY Investment Advisers reported no remaining Principia Biopharma Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • FNY Investment Advisers sold 145 Principia Biopharma Inc. Common Stock shares in Q4 2018, an estimated $4K.
  • FNY Investment Advisers first reported a position in Principia Biopharma Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • FNY Investment Advisers's Principia Biopharma Inc. Common Stock position peaked at $4K in Q3 2018.
  • 53 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q4 2018.

Based on FNY Investment Advisers's 13F filing for Q4 2018, filed 22 Jan 2019.